Search research articles
Contact Us
Filters
Showing results (81-90 of 123) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik, Glen J Weiss, John E Leonard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2012
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
Toshio Shimizu, Anthony W Tolcher, Kyriakos P Papadopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Jeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2008
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M Mita, Alain C Mita, Quincy S Chu, et al.
Cancer Chemotherapy and Pharmacology
|
June 1, 2006
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
Monica M Mita, Eric K Rowinsky, Leonardo Forero, et al.
Clinical and Translational Science
|
February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors
Jatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology
|
September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
Chia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Journal of Hematology & Oncology
|
January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 123) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik, Glen J Weiss, John E Leonard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2012
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
Toshio Shimizu, Anthony W Tolcher, Kyriakos P Papadopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Jeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2008
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M Mita, Alain C Mita, Quincy S Chu, et al.
Cancer Chemotherapy and Pharmacology
|
June 1, 2006
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
Monica M Mita, Eric K Rowinsky, Leonardo Forero, et al.
Clinical and Translational Science
|
February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors
Jatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Cancer Chemotherapy and Pharmacology
|
September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
Chia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Journal of Hematology & Oncology
|
January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
Page
of 13